Cargando…
Immunotherapy: an alternative promising therapeutic approach against cancers
The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244230/ https://www.ncbi.nlm.nih.gov/pubmed/35759082 http://dx.doi.org/10.1007/s11033-022-07525-8 |
_version_ | 1784738479570157568 |
---|---|
author | Gupta, Sneh Lata Basu, Srijani Soni, Vijay Jaiswal, Rishi K. |
author_facet | Gupta, Sneh Lata Basu, Srijani Soni, Vijay Jaiswal, Rishi K. |
author_sort | Gupta, Sneh Lata |
collection | PubMed |
description | The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11033-022-07525-8. |
format | Online Article Text |
id | pubmed-9244230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-92442302022-06-30 Immunotherapy: an alternative promising therapeutic approach against cancers Gupta, Sneh Lata Basu, Srijani Soni, Vijay Jaiswal, Rishi K. Mol Biol Rep Review The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11033-022-07525-8. Springer Netherlands 2022-06-27 2022 /pmc/articles/PMC9244230/ /pubmed/35759082 http://dx.doi.org/10.1007/s11033-022-07525-8 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Gupta, Sneh Lata Basu, Srijani Soni, Vijay Jaiswal, Rishi K. Immunotherapy: an alternative promising therapeutic approach against cancers |
title | Immunotherapy: an alternative promising therapeutic approach against cancers |
title_full | Immunotherapy: an alternative promising therapeutic approach against cancers |
title_fullStr | Immunotherapy: an alternative promising therapeutic approach against cancers |
title_full_unstemmed | Immunotherapy: an alternative promising therapeutic approach against cancers |
title_short | Immunotherapy: an alternative promising therapeutic approach against cancers |
title_sort | immunotherapy: an alternative promising therapeutic approach against cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244230/ https://www.ncbi.nlm.nih.gov/pubmed/35759082 http://dx.doi.org/10.1007/s11033-022-07525-8 |
work_keys_str_mv | AT guptasnehlata immunotherapyanalternativepromisingtherapeuticapproachagainstcancers AT basusrijani immunotherapyanalternativepromisingtherapeuticapproachagainstcancers AT sonivijay immunotherapyanalternativepromisingtherapeuticapproachagainstcancers AT jaiswalrishik immunotherapyanalternativepromisingtherapeuticapproachagainstcancers |